BMX-001

About BioMimetix JV

BioMimetix is a clinical-stage biotech advancing BMX-001, a first-in-class redox-active metalloporphyrin, towards a Phase 3 pivotal trial in high-grade glioma. The compound has demonstrated a unique dual mechanism of action that both sensitizes tumors to radiation and protects normal tissues from radiation-induced damage, supported by Phase 2 data showing a significant survival benefit. With FDA Breakthrough Therapy designation in hand, the company is leveraging its platform for multiple cancer indications, including head & neck and anal/rectal cancers, while operating as a lean, privately-held entity with a seasoned leadership team.

About BioMimetix JV

BioMimetix is a clinical-stage biotech advancing BMX-001, a first-in-class redox-active metalloporphyrin, towards a Phase 3 pivotal trial in high-grade glioma. The compound has demonstrated a unique dual mechanism of action that both sensitizes tumors to radiation and protects normal tissues from radiation-induced damage, supported by Phase 2 data showing a significant survival benefit. With FDA Breakthrough Therapy designation in hand, the company is leveraging its platform for multiple cancer indications, including head & neck and anal/rectal cancers, while operating as a lean, privately-held entity with a seasoned leadership team.

About BioMimetix JV

BioMimetix is a clinical-stage biotech advancing BMX-001, a first-in-class redox-active metalloporphyrin, towards a Phase 3 pivotal trial in high-grade glioma. The compound has demonstrated a unique dual mechanism of action that both sensitizes tumors to radiation and protects normal tissues from radiation-induced damage, supported by Phase 2 data showing a significant survival benefit. With FDA Breakthrough Therapy designation in hand, the company is leveraging its platform for multiple cancer indications, including head & neck and anal/rectal cancers, while operating as a lean, privately-held entity with a seasoned leadership team.

Therapeutic Areas